In Re Copaxone 40 MG Consolidated Cases, C.A. No. 14-1171 – GMS, February 7, 2016.
Sleet, J. Claim construction opinion issues regarding three terms from four patents. A Markman hearing took place on February 5, 2016
The disputed technology relates to the drug Copaxone. Thirty-one terms were found to be non-limiting. The following terms were considered:
- “a continuous treatment requiring three and only three subcutaneous injection each and every week [with at least one day between every injection]”
- “brain atrophy”
- “reduced severity” and “reduced frequency and severity of immediate post injection site reactions and injection site reactions”